• GH Research highlighted Phase 2b data for GH001, an inhaled mebufotenin candidate for treatment-resistant depression.
• Primary endpoint showed a least-squares mean MADRS change difference of -15.5 versus placebo on Day 8 (P<0.0001); Cohen’s d -2.
• Remission (MADRS ≤10) reached 57.5% on Day 8; open-label extension completers showed 73% remission at 6 months.
• Presentation emphasized an ~11-minute median psychoactive phase, positioning GH001 for a Spravato-compatible outpatient clinic workflow.
• Cash, cash equivalents, and marketable securities totaled $362.7 million as of June 30, 2026; Phase 3 initiation targeted in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.